Genprex found using ticker (GNPX) now have 3 analysts in total covering the stock. The consensus rating is ‘Buy’. The range between the high target price and low target price is between 8 and 5 with a mean TP of 6.67. With the stocks previous close at 3.66 this now indicates there is a potential upside of 82.2%. The 50 day moving average now sits at 3.75 and the 200 day moving average is 3.56. The market capitalisation for the company is $162m. Visit the company website at: http://www.genprex.com
Genprex operates as a clinical-stage gene therapy company that develops therapies for patients with cancer and diabetes. The company’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes. It develops drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The company’s lead product candidate REQORSA (quaratusugene ozeplasmid) for treatment for non-small cell lung cancer (NSCLC) has a multimodal mechanism of action to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis and programmed cell death in cancer cells; modulate immune response against cancer cells; and block mechanisms that create drug resistance. Genprex was founded in 2009 and is headquartered in Austin, Texas.